Effect of co-enzyme Q10 versus placebo on treatment of tinnitus due to presbycusis

Effect of co-enzyme Q10 versus placebo on treatment of tinnitus due to presbycusis: a triple-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N339

Enrollment

Registered

2020-02-07

Start date

2019-09-23

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinnitus. Tinnitus

Interventions

Intervention 1: Intervention group: Neurotriptyline tablet 25 mg (manufactured by Darupakhsh Pharmaceutical Co.) daily plus co-enzyme Q10 tablet 100 mg (manufactured by Health Aid Co.) daily for 6 wee

Eligibility

Sex/Gender

All

Age

50 Years to 90 Years

Inclusion criteria

Inclusion criteria: Age of 50 to 90 years, Tinnitus for over a year, Bilateral neural sensorineural hearing loss

Exclusion criteria

Exclusion criteria: Psychosomatic disorder, Consumption of calcium, vitamin and magnesium in the past two months, Tinnitus due to drug side effects, Atypical tinnitus, Meniere's disease, Conductive hearing loss

Design outcomes

Primary

Measure	Time frame
Severity of tinnitus. Timepoint: Before the intervention and 6 months later. Method of measurement: Using the Tinnitus Handicap Inventory (THI).;Sleep disorder. Timepoint: Before the intervention and 6 months later. Method of measurement: Using the Petersburg questionnaire.;Quality of life. Timepoint: Before the intervention and 6 months later. Method of measurement: Using the SF-36 questionnaire.	—

Measure

Time frame

Severity of tinnitus. Timepoint: Before the intervention and 6 months later. Method of measurement: Using the Tinnitus Handicap Inventory (THI).;Sleep disorder. Timepoint: Before the intervention and 6 months later. Method of measurement: Using the Petersburg questionnaire.;Quality of life. Timepoint: Before the intervention and 6 months later. Method of measurement: Using the SF-36 questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Zahra Sadeghi

Hamedan University of Medical Sciences

sazcsaz66@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026